Annovis Bio Q3 Loss Narrows to $0.22 as DUET-AD Readout Set for March 2027

Annovis Bio, Inc. (NYSE: ANVS) reported a third-quarter 2026 net loss of $9.46 million, or $0.22 per basic and diluted share, on 13 November 2026, narrowing from a $0.37 per-share loss a year earlier. The Malvern, Pennsylvania-based Phase 3 biotechnology company closed a $21.0 million gross underwritten public offering on 6 November 2026 and said the proceeds should fund operations through the 6-month data readout from its pivotal DUET-AD Alzheimer's trial, expected in March 2027. Cash and cash equivalents stood at $2.8 million as of 30 September 2026.

Context — Why Annovis Bio's Cash Runway Matters Now

Annovis is a clinical-stage company with no approved product and no revenue line in the reported statements. Its operations are funded entirely from capital markets, which makes the size and timing of the November raise as material to the equity story as any trial datapoint.

The company's own comparison shows the burn accelerating. Research and development expenses for the three months ended 30 September 2026 reached $15.8 million, against $6.3 million for the same quarter of 2025 — roughly two and a half times the prior-year figure. That step-up reflects a trial in execution rather than enrollment, as the company moves from recruiting patients into DUET-AD toward monitoring, data cleaning and preparation for a filing.

Cash fell to $2.8 million at quarter-end from $19.5 million at 31 December 2025. Total stockholders' equity swung to a deficit of $13.2 million from positive $16.9 million over the same period, a direct consequence of the accumulated deficit reaching $205.6 million.

The balance sheet now carries a $12.47 million warrant liability, up from $595,000 at year-end 2025. That line moved largely because of a non-cash change in the fair value of warrants, which contributed $7.46 million of other income in the quarter and helped narrow the reported net loss.

What changed to trigger the financing now is timing. The company said the last patient, last visit of the 6-month treatment period in DUET-AD is scheduled for 31 December 2026, with database lock on 8 February 2027 and topline data in March 2027. That schedule, disclosed alongside the quarter, is the catalyst the raise is sized against.

Data — What Annovis Bio's Numbers Show

The reported quarter pairs a widening operating loss with a smaller per-share loss, because the share count grew. Weighted-average basic and diluted shares rose to 42.63 million from 19.69 million a year earlier, following the increase in common stock outstanding to 42.69 million shares at 30 September 2026 from 27.20 million at 31 December 2025.

Metric	Q3 2026	Q3 2025
Net loss	$9.46M	$7.26M
Net loss per share	$0.22	$0.37
R&D expense	$15.78M	$6.29M
G&A expense	$1.19M	$1.14M

The nine-month picture is starker. Research and development for the nine months ended 30 September 2026 was $44.5 million against $16.5 million a year earlier, and the year-to-date net loss widened to $41.9 million from $19.0 million.

Total operating expenses for the quarter were $16.97 million versus $7.43 million. Interest income fell to $84,868 from $152,317, consistent with a smaller average cash balance. The company also recorded $37,896 of other financing costs in the quarter, a line that did not exist a year earlier.

On the clinical side, DUET-AD is fully enrolled with 862 patients who have early Alzheimer's disease and are positive for the plasma biomarker pTau217. The OLE-PD Parkinson's extension has enrolled 326 patients, with new-patient enrollment projected to close on 29 January 2027. No peer or sector index comparison was provided in the report.

Analysis — What It Means for ANVS and Biotech Investors

The mechanics of the quarter matter more than the headline loss. Annovis holds a cash balance far below its quarterly R&D run rate, and the November offering is what bridges the gap to the March readout. The company said the Chairman of the Board contributed $5.0 million of the offering, an insider participation that signals alignment but does not change the dilution already absorbed by existing holders.

Second-order effects run through the Alzheimer's drug-development complex. DUET-AD's dual design — a 6-month symptomatic readout and an 18-month disease-modifying readout — means the March 2027 event is a partial result, not the end of the study. The company said patients continue treatment for an additional 12 months, and it plans to present the 6-month data at the AD/PD 2027 conference in Barcelona. Any read on buntanetap, an oral therapy targeting translation of multiple neurotoxic proteins, would inform sentiment across oral small-molecule neurodegeneration programs broadly, not just ANVS.

The clearest counter-argument is that a 6-month symptomatic endpoint is a lower bar than the 18-month disease-modifying one, and a positive signal there would not settle the longer question. Investors should also weigh the warrant liability: it swings reported earnings on non-cash fair-value moves, so quarterly net loss is a noisy gauge of operating performance.

Positioning is binary by nature. Holders are effectively long a single clinical event, while the warrant overhang and the enlarged share count cap upside for late entrants. Flow into the name is likely to stay event-driven until the database locks.

Outlook — What to Watch for ANVS

The near-term calendar is defined by three dates the company disclosed. The last patient, last visit of the DUET-AD 6-month period is scheduled for 31 December 2026; database lock is set for 8 February 2027; and topline results are expected in March 2027. Enrollment of new patients in OLE-PD is projected to complete on 29 January 2027.

Before the readout, Annovis said it aims to prepare a significant part of a planned New Drug Application for buntanetap, using a partnership with Weave Bio announced in September. The company also pointed to three presentations at CTAD 2026 in Boston from 16 to 19 November, plus panel appearances at U.S. Biotech Day and the Pharma Partnering Summit.

The report named no price levels, moving averages or index thresholds, so no technical reference points apply here. The operative variables are the March data and whether the $21.0 million carries operations to it as the company expects.

Frequently Asked Questions

What does the $21.0 million raise mean for Annovis Bio shareholders?

The offering closed on 6 November 2026 with gross proceeds of about $21.0 million, and the company said it should fund operations through the DUET-AD 6-month readout in March 2027. Because Annovis has no product revenue, the raise is essential to reaching that catalyst. It also increased the share count, which is why the per-share loss narrowed even as the absolute net loss widened year over year.

What is the difference between the 6-month and 18-month DUET-AD readouts?

The company designed DUET-AD with two prespecified analyses: a 6-month symptomatic readout and an 18-month disease-modifying readout. The March 2027 event covers only the 6-month period. Annovis said patients continue treatment for an additional 12 months after that point, so the longer-term question about halting disease progression remains open well beyond the first data release.

Why did Annovis Bio's net loss narrow while its R&D spending rose?

Operating expenses rose, with R&D at $15.8 million for the quarter versus $6.3 million a year earlier. The reported net loss narrowed because of non-operating items, chiefly a $7.46 million non-cash gain from the change in fair value of warrants. That gain pulled total other income to $7.5 million, partially offsetting the larger operating loss. It is an accounting effect, not a cash inflow.

Bottom Line

Annovis Bio has financed itself to a binary March 2027 readout, with a $2.8 million cash pile and a $21.0 million raise carrying the story.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.